science
Dualitas Therapeutics and Roche Partner to Discover Bispecific Antibodies for I&I Diseases

Dualitas Therapeutics has announced a research collaboration and licence agreement with Roche to discover and develop novel bispecific antibody (BsAb) therapies for immunology and inflammation (I&I) diseases. The DualScreenTM platform is designed to support high-throughput discovery of bispecific antibodies based on proximity biology. Unlike conventional approaches that typically begin with selected target pairs, the platform evaluates a broad range of targets and epitopes
ONLY AVAILABLE IN PAID PLANS
Read Full ArticleShare this story
Up next
Related Stories

Mouse study reveals magnetic nanoparticles' potential for ectopic pregnancy diagnosis and treatment
Phys.org

Wood beneath German lake may reveal buildings 3,000 years older than region's first farms
Phys.org

Seventeen K-Pop Robots Take Over Rockefeller Center, One Demands to Be Called a Soul
Hoodline

Four Sets of Abstract Moral Systems
Overcoming Bias Economics Blog

A home for ‘Inspiration': See the space shuttle mockup's future Downey building
Nbc Los Angeles